Windlas Biotech Limited (BOM:543329)
India · Delayed Price · Currency is INR 883.10
+6.35 (0.72%)
At close: Apr 21, 2026
Windlas Biotech Revenue
Windlas Biotech had revenue of 2.33B INR in the quarter ending December 31, 2025, with 19.53% growth. This brings the company's revenue in the last twelve months to 8.68B, up 19.20% year-over-year. In the fiscal year ending March 31, 2025, Windlas Biotech had annual revenue of 7.60B with 20.43% growth.
Revenue (ttm)
8.68B
Revenue Growth
+19.20%
P/S Ratio
2.13
Revenue / Employee
6.45M
Employees
1,346
Market Cap
18.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 7.60B | 1.29B | 20.43% |
| Mar 31, 2024 | 6.31B | 1.18B | 22.97% |
| Mar 31, 2023 | 5.13B | 471.53M | 10.12% |
| Mar 31, 2022 | 4.66B | 383.28M | 8.96% |
| Mar 31, 2021 | 4.28B | 987.50M | 30.03% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Unichem Laboratories | 22.14B |
| Morepen Laboratories | 17.87B |
| Hikal | 17.46B |
| Bliss GVS Pharma | 8.68B |
| TTK Healthcare | 8.30B |
| Venus Remedies | 7.03B |
| Syncom Formulations (India) | 5.03B |
| Amrutanjan Health Care | 4.88B |